DiaMedica Therapeutics Inc. (DMAC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

DiaMedica Therapeutics Inc. (DMAC) closed at USD 7.66 on 2026-10-14, a change of +12.8 % over the past year, with a market capitalization of USD 433.56M.

DiaMedica Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

DiaMedica Therapeutics Inc. key figures

Previous close

USD 7.66 (2026-10-14)

1-year change

+12.8 %

Market cap

USD 433.56M

Enterprise value

USD 390.24M

P/E ratio (trailing)

-11.17

P/E ratio (forward)

-9.95

EPS (trailing)

-0.72

EPS (forward)

-0.81

PEG ratio

n/a

Price to book

11.31

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

28.38

Employees

35

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for DiaMedica Therapeutics Inc. and compare it with other stocks.